ovarian adnexal mass
Aspira Women's Health Offers $1.9M in Stock Through Private Placement
The company has offered roughly 1.3 million shares of common stock and warrants to purchase an equal number of shares at a combined price of $1.53 per share.
Aspira Announces $5.5M Direct Offering, Concurrent Private Placement
Aspira is selling shares and warrants to an institutional investor, existing shareholders, and CEO Nicole Sandford to raise funds for general corporate purposes.
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.
Aspira Women's Health Q3 Revenues Up 34 Percent
The cancer diagnostics firm posted $1.7 million in revenues, up from $1.2 million the year prior, and completed 4,281 OVA ovarian cancer tests.
Aug 12, 2021
Aspira Q2 Revenues More Than Double
May 14, 2021
Nov 12, 2020
Aspira Q3 Revenues Down 8 Percent
Aug 13, 2020
Aspira Q2 Revenues Down 32 Percent
Jul 1, 2020
Aspira Eyes $11M in Private Equity Financing
May 14, 2020
Vermillion Q1 Revenues Up 55 Percent
Mar 26, 2020
Vermillion Q4 Revenues Up 42 Percent
Nov 13, 2019
Nov 12, 2019
Vermillion Q3 Revenues Up 66 Percent
May 14, 2019
Vermillion Q1 Revenues Up 24 Percent
Mar 28, 2019
Vermillion Q4 Revenues Up 16 Percent
Jan 15, 2019
Cigna Covering Vermillion's OVA1 Ovarian Cancer Test
Dec 13, 2018
Nov 8, 2018